Mutant p53 reactivation by small molecules makes its way to the clinic

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• The TP53 tumor suppressor gene is frequently mutated in human cancers, leading to dysfunctional p53 protein.
• Mutant p53 proteins accumulate at high levels in tumor cells, contributing to cancer progression.
• Restoring wild-type p53 function holds therapeutic potential for cancer treatment.

Purpose of the Study:

• To explore therapeutic strategies targeting mutant TP53 in cancer.
• To identify and evaluate small molecules capable of rescuing mutant p53 function.

Main Methods:

• Review of therapeutic approaches targeting mutant p53.
• Identification of small molecules that restore wild-type p53 activity.
• Mention of specific compounds like PK083, PK5174, NSC319726, PRIMA-1, and APR-246.
• Clinical trial data for APR-246.

Main Results:

• Several small molecules have been identified that can rescue specific or a range of mutant p53 proteins.
• Compounds like APR-246 show promise in targeting various mutant p53 forms.
• APR-246 has demonstrated promising results in a Phase I/II clinical trial.

Conclusions:

• Targeting mutant TP53 is a viable and developing therapeutic strategy in cancer research.
• Small molecules capable of restoring p53 function offer a promising avenue for tumor eradication.
• APR-246 represents a potential therapeutic agent for cancers with TP53 mutations.